The global ophthalmic drugs market is expected to grow at a CAGR of 4.8% in the first half of the forecast period. The market is estimated at $25bn in 2018, dominated by the retinal disorder drugs segment.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 298-page report you will receive 138 tables and 125 figures– all unavailable elsewhere.
The 298-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Ophthalmic Drugs market forecasts from 2019-2029
• This report also breaks down the revenue forecasts to 2029 for the global ophthalmic drugs market by the leading submarkets:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs
• This report includes revenue forecasts to 2029 for the following ophthalmic drugs:
• Eylea
• Lucentis
• Avastin
• Visudyne
• Jetrea
• Pataday
• Vigamox
• Patanol
• TobraDex
• Cravit
• AzaSite
• Acular
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Azopt
• Trusopt
• Zioptan
• Cosopt
• Tapros/Taflotan
• Restasis
• Refresh
• Hyalein
• Diquas
• This report provides individual revenue forecasts to 2029 for these national markets:
• The US
• Japan
• EU5: Germany, France, the UK, Spain, Italy
• Russia
• China
• India
• Brazil
• Rest of the World
Each national market is further segmented by the leading submarket: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs, Other Ophthalmic Drugs
• Our study provides a SWOT analysis and discusses Porter’s Five Forces analysis that influence the global ophthalmic drugs market
• Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline
• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
• Allergan (Actavis)
• Bayer
• Novartis
• Pfizer
• Regeneron
• Roche
• Santen
• Senju
• Valeant
• Key Questions Answered by this Analysis:
• How is the market for ophthalmic drugs evolving?
• What is driving and restraining the ophthalmic drugs market dynamics?
• What are the market shares of the submarkets for glaucoma drugs, allergic, inflammatory and infective drugs, dry eye drugs and retinal disorder drugs from the overall ophthalmic Drugs Market in 2018?
• How will each of the submarket segments within the ophthalmic drugs market grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each of the submarkets within the ophthalmic drugs market develop from 2018 to 2029?
• Which submarkets will be the main driver of growth in the overall market from 2018 to 2029?
• How will political, economic, and regulatory factors influence the regional markets and submarkets?
• Will the leading regional markets for ophthalmic drugs broadly follow pre-existing trends, or will individual regions outperform the rest of the market?
• How will the regional market shares in the ophthalmic drugs market change by 2029 and which geographical region will lead the market in 2029?
• What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry sector evolve as cost and pricing pressures increase during the period between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.
Buy our report today Global Ophthalmic Drugs Market Forecast 2019-2029: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate and Functionally Intricate Organs
2.3 The Global Burden of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause of Vision Loss
2.5.1 A Classification of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors for Glaucoma
2.5.3 Diagnosis of Glaucoma
2.5.4 Drug Treatment of Glaucoma
2.5.5 Laser Treatment and Surgery for Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors for AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis of Diabetic Retinopathy
2.7.2 Risk factor of Diabetic Retinopathy
2.7.3 Treatment of Diabetic Retinopathy
2.8 Ocular Allergy and Allergic Conjunctivitis
2.8.1 Diagnosis of Ocular Allergy
2.8.2 Treatment of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Risk factors of Ocular Inflammatory Disease
2.9.2 Treatment of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition in This Report
3. The Global Ophthalmic Drugs Market, 2019-2029
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation of the Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2018
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2018-2029
3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2019-2029
4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2019-2029
4.1 Leading Products in the Retinal Disorder Drugs Market, 2018
4.2 Retinal Disorders: Market Trends and Developments, 2018
4.2.1 The Rise of Eylea
4.2.2 The Debate Around Off-Label Avastin Use and The Role of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline
4.2.5 Drug/Device Combination Products Entering the Market
4.2.6 Does Regenerative Medicine Have a Successful Future in Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2019-2029
4.3.1 Retinal Disorder Drugs: Changing Market Shares by Leading Drugs 2019-2029
4.4 Leading Drugs for The Treatment of Retinal Disorders
4.5 Eylea (aflibercept) - Regeneron/ Bayer/ Santen
4.5.1 Recent Approvals for Eylea
4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.5.3 Eylea: Sales Forecast 2019-2029
4.5.4 Possible Combination Therapies Involving Eylea
4.6 Lucentis (ranibizumab) – Roche/ Novartis
4.6.1 Lucentis: Sales Forecast 2019-2029
4.6.2 Less Frequent Dosing Approved in US for Lucentis
4.6.3 New Indications for Lucentis
4.6.4 Possible Combination Therapy Involving Lucentis
4.7 Avastin (bevacizumab) - Roche
4.7.1 Avastin: Sales Forecast 2019-2029
4.7.2 Compounding Pharmacies and Safety Risks
4.8 Visudyne (verteporfin) - Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2019-2029
4.9 Jetrea (ocriplasmin) - ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans for Jetrea
4.9.3 Jetrea: Sales Forecast 2019-2029
4.9.4 Possible Acquisition Move on ThromboGenics
4.9.5 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) - Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) - Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2018-2029
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis and Forecast 2019-2029
5.1 Leading Products in The Allergic, Inflammatory and Infective Drugs Market, 2018
5.2 Allergic, Inflammatory and Infective Drugs: Market Trends and Developments, 2018
5.2.1 The Growth Prospects for Allergic, Inflammatory and Infective Drugs
5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro
5.3 Allergic, Inflammatory and Infective Drugs: Market Forecast 2019-2029
5.3.1 Allergic, Inflammatory and Infective Drugs: Changing Market Shares by Leading Drugs 2019-2029
5.4 Leading Drugs for The Treatment of Allergic, Inflammatory and Infective Ophthalmic Conditions
5.5 Patanol And Pataday (olopatadine) - Alcon (Novartis)
5.5.1 Pataday: Sales Forecast 2018-2029
5.5.2 Impending Generic Competition for Patanol And Pataday
5.5.3 Approval of Pazeo Solution
5.5.4 Patanol: Sales Forecast 2019-2029
5.6 Vigamox (moxifloxacin) – Alcon (Novartis)
5.6.1 Intensifying Competition and Generics Drug Challenge to Vigamox
5.6.2 Moxeza: A Next-Generation Form of Vigamox
5.6.3 Vigamox: Sales Forecast 2019-2029
5.7 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.7.1 The Development and Commercialisation of TobraDex ST
5.7.2 TobraDex: Sales Forecast 2019-2029
5.8 Cravit (levofloxacin) - Santen
5.8.1 Cravit: Sales Forecast 2019-2029
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 Acular: Sales Forecast 2019-2029
5.10 AzaSite (azithromycin) - Akorn
5.10.1 AzaSite: Sales Forecast 2019-2029
5.11 Other Allergic, Inflammatory, and Infective Drugs: Sales Forecast 2019-2029
6. Glaucoma Drugs Market: Market Analysis and Forecast 2019-2029
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products in The Glaucoma Drugs Market, 2018
6.2 Glaucoma Drugs: Market Trends and Developments, 2018
6.2.1 Patent Expiration: A Major Restraint for Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation in Treatments for Glaucoma
6.3 Simbrinza: First Beta-Blocker-Free Combination
6.4 Glaucoma Drugs: Market Forecast 2019-2029
6.4.1 Glaucoma Drugs: Changing Market Shares by Leading Drugs 2019-2029
6.5 Leading Drugs for The Treatment of Glaucoma
6.6 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.6.1 Lumigan And Ganfort: Sales Forecast 2018-2029
6.7 Xalatan And Xalacom (latanoprost) - Pfizer
6.7.1 Xalatan/Xalacom: Sales Forecast 2019-2029
6.8 Travatan/Travatan Z and DuoTrav (travoprost) - Novartis
6.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2019-2029
6.9 Alphagan/Alphagan P and Combigan (brimonidine) - Allergan
6.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2019-2029
6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.10.1 Divestment Agreement with Santen And Akorn
6.10.2 Trusopt: Sales Forecast 2019-2029
6.10.3 Cosopt And Cosopt PF: Sales Forecast 2019-2029
6.11 Azopt (brinzolamide) - Novartis
6.11.1 Azopt: Sales Forecast 2019-2029
6.12 Tapros (tafluprost) – Santen
6.12.1 Tapros: Sales Forecast 2019-2029
6.13 Zioptan (tafluprost) - Akorn
6.13.1 Zioptan: Sales Forecast 2019-2029
6.14 Other Glaucoma Drugs: Sales Forecast 2019-2029
7. Dry Eye Drugs Market: Market Analysis and Forecast 2019-2029
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products in The Dry Eye Drugs Market, 2018
7.2 Dry Eye Drugs: Market Trends and Developments, 2018
7.2.1 Restasis: Patent Elongations and Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused on Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2019-2029
7.3.1 Dry Eye Drugs: Changing Market Shares by Leading Drugs 2019-2029
7.4 Leading Drugs for The Treatment of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis – Generic launch in 2016?
7.5.2 Restasis: Sales Forecast 2019-2029
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2019-2029
7.7 Hyalein (hyaluronic acid) - Santen
7.7.1 Hyalein: Sales Forecast 2019-2029
7.8 Diquas (diaquafosol) - Santen
7.8.1 Diquas: Sales Forecast 2019-2029
7.9 Other Dry Eye Drugs: Sales Forecast 2019-2029
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) - Vanda Pharmaceuticals
7.10.2 Hetlioz: Sales Forecast 2019-2029
8. Leading National Markets for Ophthalmic Drugs, 2019-2029
8.1 The Ophthalmic Drugs Market by Region
8.1.1 The Global Distribution of Ophthalmic Drugs In 2018
8.2 Leading National Markets: Forecast 2019-2029
8.2.1 Changing Market Shares by Region, 2019-2029
8.3 Regional Ophthalmic Drugs Markets: Analysis and Forecasts, 2019-2029
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will the Rise of a Biosimilars Market Impact on US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2018-2029
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2018-2029
8.5.1.1 EU5 Markets: Changing Market Shares by Country, 2019-2029
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2019-2029
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2019-2029
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2019-2029
8.5.4.2 Brexit – Increased Uncertainty May Affect the UK Ophthalmic Drug Market
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2019-2029
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2019-2029
8.6 Japan
8.6.1 The Cost of Treatment in Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2019-2029
8.7 China
8.7.1 Expansion of Healthcare Coverage and Reimbursement in China
8.7.2 Price Controls and The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2019-2029
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2019-2029
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2019-2029
8.10 India
8.10.1 The Impact of The Drug Prices Control Order on Indian Pharma
8.10.2 India’s Expansion of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2019-2029
8.11 Rest of the World
8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2019-2029
9. Leading Companies in the Ophthalmic Drugs Market, 2019-2029
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.2 Leading Companies in The Ophthalmic Drugs Market, 2018
9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2019-2029
9.2.2 Ophthalmic Drugs: Changing Market Shares by Leading Companies 2019-2029
9.3 Novartis (Alcon)
9.3.1 Novartis: Ophthalmic Drugs Portfolio
9.3.2 Novartis: Sales Forecast 2019-2029
9.3.3 Novartis: Ophthalmic Drugs Development Pipeline
9.3.4 Novartis: Recent Developments
9.3.4.1 Novartis Restructures Following Strategic Review
9.3.4.2 Novartis Licenses Ophthotech’s Fovista
9.4 Regeneron
9.4.1 Regeneron: Ophthalmic Drugs Portfolio
9.4.2 Regeneron: Recent Developments
9.4.2.1 Expanding Indications for Eylea
9.4.2.2 Eylea/Zaltrap And the Davis-Smyth Patent Agreements
9.4.3 Regeneron: Sales Forecast 2019-2029
9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline
9.5 Allergan (Actavis)
9.5.1 Allergan: Ophthalmic Drugs Portfolio
9.5.2 Allergan: Recent Developments
9.5.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.5.2.2 How Real Is the Threat of Generic Restasis?
9.5.2.3 Valeant’s Attempted Takeover Squashed by Actavis Bid
9.5.3 New acqusitions for healthcare development
9.5.4 Allergan: Sales Forecast 2019-2029
9.5.5 Allergan: Ophthalmic Drugs Development Pipeline
9.6 Roche
9.6.1 Roche: Ophthalmic Drugs Portfolio
9.6.1.1 Lucentis: US Sales Forecast 2019-2029
9.6.2 Roche: Sales Forecast 2019-2029
9.6.3 Roche: Ophthalmic Drugs Development Pipeline
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio
9.7.2 Valeant: Recent Developments
9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
9.7.3 Valeant: Sales Forecast 2019-2029
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline
9.7.5 Valeant: Difficult End to 2015 as well as 2016 Leads to Uncertainty About Company Future
9.8 Santen
9.8.1 Santen: Ophthalmic Drugs Portfolio
9.8.2 Santen: Recent Developments
9.8.2.1 Santen Acquires Novagali Pharma
9.8.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.8.3 Santen: Sales Forecast 2019-2029
9.8.4 Santen: Ophthalmic Drugs Development Pipeline
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2019-2029
9.10 Pfizer
9.10.1 Pfizer: Ophthalmic Drugs Portfolio
9.10.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products
9.10.1.2 Macugen - Valeant/Pfizer
9.10.2 Pfizer: Recent Developments
9.10.2.1 Pfizer Attempts to Acquire AstraZeneca
9.10.2.2 Pfizer Attempts Merger with Allergan
9.10.3 Pfizer: Sales Forecast 2019-2029
9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline
9.11 Senju
9.11.1 Senju: Ophthalmic Drugs Portfolio
9.11.2 Senju: Sales Forecast 2019-2029
9.11.3 Senju: Ophthalmic Drugs Development Pipeline
9.11.3.1 Y 39983 (SNJ 1656)
9.11.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs: Research and Development Pipeline, 2019-2029
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts in Retinal Disorders
10.2 Drugs for Retinal Disorders: Development Pipeline
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.3 Retinal Disorders: Filed or Recently Launched
10.3.1 CompaqSipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.3.2 Lipidil (fenofibrate) - Abbott
10.3.3 Iluvien (fluocinolone) – Alimera Sciences
10.4 Drugs in Phase 3 Development for Retinal Disorders
10.4.1 AGN150998 And MP0260 (Anti-VEGFDARPins) - Allergan
10.4.2 Fovista and Zimura – Ophthotech Corporation
10.4.3 Lampalizumab (anti-FactorD Fab) - Roche
10.4.4 MC-1101 (hydralazine) – Macu CLEAR
10.4.5 Squalamine (anti-angiogenic drug) - OHRPharmaceutical
10.4.6 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.4.7 UF-021 (unoprostone) - R-TechUeno
10.5 Drugs in Phase 2 Development for Retinal Disorders
10.5.1 AKB-9778 (Tie2 activator) - AerpioTherapeutics
10.5.2 Luminate (ALG-1001; Integrin peptide therapy) - Allegro/Senju
10.5.3 AGN208397 (beclomethasone) - Allergan
10.5.4 CPC 551 - ColbyPharmaceutical
10.5.5 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) - iCo Therapeutics
10.5.7 LFG316 (anti-C5 mAb) - Novartis
10.5.8 Intravitreal brimonidine implant - Allergan
10.5.9 Optina (danazol) – Ampio Pharmaceuticals
10.5.10 PF-655 (synthetic siRNA) - Quark/Pfizer
10.5.11 Premiplex (SHP-607) - Shire
10.5.12 Renexus (ciliary neurotrophic factor) - Neurotech
10.5.13 Zybrestat (fosbretabulin) - Oxigene/SymphonyVIDA
10.6 DrugsInPhase 1 and Pre-clinical Developmentfor RetinalDisorders
10.6.1 BDM-E - BioDiem
10.6.2 NADPHOxidaseInhibitors – AlimeraSciences
10.6.3 PAN-90806 (topical VEGF inhibitor) - PanOptica
10.6.4 PlasmaKallikreinInhibitors (KVD001) - KalVista
10.6.5 QLT091001 (synthetic retinoid) – QLT
10.7 Drugs in Phase 3 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
10.7.1 EGP-437 (dexamethasone) – EyeGate Pharmaceuticals
10.7.2 IBI-10090 and IBI-20089 - IconBioscience
10.7.3 KPI-121 (loteprednol etabonate) - Kala
10.8 Drugs in Phase 2 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
10.8.1 CF101 (adenosine A3 receptor agonist) - Can-Fite BioPharma and OphthaliX
10.8.2 FST-100 (povidone-iodine/dexamethasone) - Shire
10.8.3 NVC-422 (auriclosene) - NovaBay
10.8.4 Sarilumab - Regeneron
10.9 Drugs in Phase 1 And Pre-clinical Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
10.9.1 Finafloxacin – MerLion Pharmaceuticals/Novartis
10.10 Drugs for Glaucoma: Development Pipeline, 2016
10.11 Drugs in Phase 2&3 Development for Glaucoma
10.11.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant
10.11.2 AMA0076 (ROCK inhibitor) - Amakem
10.11.3 Rhopressa (AR-13324; ROCK and NET inhibitor) AndRoclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.12 Drugs in Phase 1 And Pre-clinical Development for Glaucoma
10.13 Drugs in Phase 3 Development for Dry Eye
10.13.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.13.2 Lifitegrast (integrin antagonist) - Shire
10.13.3 Tavilermide (formerly MIM-D3tyrosine kinase receptor antagonist) - Allergan
10.13.4 SI-614 (modified hyaluronate) - Seikagaku
10.14 Drugs in Phase 2 Development for Dry Eye
10.14.1 ESBA105 (TNF-alpha antibody) - Alcon (Novartis)
10.14.2 Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi
10.15 Other Drugs in the Development Pipeline for Ophthalmic Conditions
10.15.1 Brimonidine For Eye Whitening - Valeant
10.15.2 GS-101 (aganirsen) - GeneSignal
10.15.3 Omidria (phenylephrine/ketorolac) – Omeros
11. Qualitative Analysis of the Ophthalmic Drugs Market, 2019-2029
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis of the Global Ophthalmic Drugs Market, 2019-2029
11.3 Strengths
11.3.1 A Healthy R&D Pipeline
11.3.2 Advances in Drug Delivery Technologies
11.3.3 Support for Reimbursement and Payment Approvals
11.3.4 Gene Therapy and RNAi Technology
11.3.5 New Ophthalmic Therapeutic Applications for Drugs
11.3.6 Development of Neuroprotective Anti-Glaucoma Medications
11.3.7 Biomarkers as Tools for Better Diagnosis and Treatment
11.4 Weaknesses
11.4.1 Low Levels of Patient Adherence to Treatment
11.4.2 High Treatment Burden on Patients and Healthcare Providers
11.4.3 Under-Diagnosis and Under-Treatment
11.5 Opportunities
11.5.1 Sustained-Release Ocular Implants
11.5.2 The Impact of a Rapidly Ageing Global Population
11.5.3 Increasing Prevalence of Diabetes and Ocular Disease
11.5.4 Glaucoma and Retinal Disorders Set for Most-Marked Increases in Prevalence
11.5.5 Unmet Clinical Need in Many Disease Areas
11.5.6 Economic Growth in Emerging Market Provide Opportunity for Expansion
11.6 Threats
11.6.1 Intensifying Price Regulation in The Market
11.6.2 Generic Competition – Likely to Cause Erosion of Sales for Market Leading Brands
11.6.3 Rising Cost Of R&D
11.6.4 Biosimilars – A Bigger Threat than Generics?
11.7 Porter’s Five Force Analysis of The Global Ophthalmic Drugs Market, 2019-2029
11.7.1 Threat of New Entrants
11.7.2 Rivalry Among Competitors
11.7.3 Power of Suppliers
11.7.4 Threat of Substitutes
11.7.5 Power of Buyers
12. Conclusions
12.1 Overview of Current Market Conditions and Market Forecast, 2019-2029
12.2 Leading Sectors in Ophthalmic Drugs In 2018
12.3 Leading Regions in the Ophthalmic Drugs Market In 2018
12.4 Leading Companies in The Ophthalmic Drugs Market, 2018
12.5 What Does the Future Hold for Ophthalmic Drugs?
Appendices
Glossary
Associated Reports
Visiongain Report Sales Order Form
List of Tables
Table 2.1 ICD 10 Classification of Visual Impairment, 2010
Table 2.2 Main Classes of the Glaucoma Drugs
Table 2.3 Drug Treatments for Age-Related Macular Degeneration, 2017
Table 2.4 Drug Treatments for Ocular Allergy
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2017
Table 2.6 Drug Treatments for Eye Infections, 2017
Table 2.7 Clinical Trial Phases
Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2018
Table 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
Table 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2018-2023, 2023-2029, 2018-2029
Table 3.4 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Sector, 2018, 2023, 2029
Table 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2018
Table 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029
Table 4.3 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029
Table 4.4 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.5 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 4.6 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 4.7 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 4.8 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 4.9 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2018
Table 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029
Table 5.3 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029
Table 5.4 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 5.5 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 5.6 Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 5.7 TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 5.8 Cravit: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 5.9 Acular: Sales Forecast ($m, AGR%, CAGR%), 2018-2029
Table 5.10 AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 6.1 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2018
Table 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029
Table 6.3 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029
Table 6.4 Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2018-2029
Table 6.5 Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 6.6 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 6.7 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 6.8 Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 6.9 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 6.10 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 6.11 Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2018-2029
Table 6.12 Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 6.13 Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 7.1 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2018
Table 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029
Table 7.3 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029
Table 7.4 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 7.5 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 7.6 Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 7.7 Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 7.8 Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2019-2029
Table 7.9 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2018
Table 8.2 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2019-2029
Table 8.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2018-2023, 2023-2029, and 2018-20289
Table 8.4 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2018, 2023, and 2029
Table 8.5 The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.6 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.7 The US Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.8 EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2018-2029
Table 8.9 EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2018
Table 8.10 EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.11 EU5 Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.12 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2018, 2023, 2029
Table 8.13 The German Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.14 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.15 The Germany Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.16 The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.17 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.18 France Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.19 The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.20 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.21 UK Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.22 The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.23 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.24 Italy Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.25 The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.26 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.27 Spain Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.28 The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.29 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.30 Japan Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.31 The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.32 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.33 China Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.34 The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
Table 8.35 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.36 Brazil Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.37 The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028
Table 8.38 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.39 Russia Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.40 The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.41 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.42 India Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 8.43 The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
Table 8.44 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 8.45 Row Ophthalmic Drugs Market Forecast by Sector, 2019-2029
Table 9.1 Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2018
Table 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2019-2029
Table 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2018, 2023, 2029
Table 9.4 Novartis: Company Overview, 2018
Table 9.5 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.6 Regeneron: Company Overview, 2018
Table 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.8 Allergan: Company Overview, 2018
Table 9.9 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.10 Roche: Company Overview, 2018
Table 9.11 Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.12 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.13 Valeant: Company Overview, 2018
Table 9.14 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.15 Santen: Company Overview, 2016
Table 9.16 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.17 Bayer: Company Overview, 2018
Table 9.18 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.19 Pfizer: Company Overview, 2016
Table 9.20 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.21 Senju: Company Overview, 2018
Table 9.22 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.23 Other Companies: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
Table 10.1 Retinal Disorders Drugs Pipeline: Phase 3 Drugs
Table 10.2 Retinal Disorders Drugs Pipeline: Phase 2 Drugs
Table 10.3 Retinal Disorders Drugs Pipeline: Phase 1 and Pre-clinical Drugs
Table 10.4 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 3 Drugs
Table 10.5 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 2 Drugs
Table 10.6 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 1 and Pre-clinical Drugs
Table 10.7 Glaucoma Drugs Pipeline: Phase 2&3 Drugs
Table 10.8 GlaucomaDrugsPipeline: Phase 1 and Pre-clinical Drugs
Table 10.9 DryEyeDrugsPipeline: Phase 3 Drugs
Table 10.10 DryEyeDrugsPipeline: Phase 2 Drugs
Table 10.11 OtherPipelineProducts for OphthalmicConditions
Table 11.1 SWOT Analysis of the Global Ophthalmic Drugs Market, 2019-2029
Table 11.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2017-2028
Table 11.3 Global Prevalence Forecast for Ophthalmic Diseases
Table 12.1 Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2018, 2023 and 2029
Table 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2018, 2023, 2029
Table 12.3 Top ten ophthalmic drug companies in 2018
List of Figures
Figure 1.1 Global Ophthalmic Drugs Market: Market Sectors, 2018
Figure 2.1 Structure of The Human Eye
Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2014
Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012
Figure 2.4 Classification of Glaucoma, 2016
Figure 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2018
Figure 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2018-2023
Figure 3.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2023-2029
Figure 3.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2018-2029
Figure 3.6 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2018
Figure 3.7 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2023
Figure 3.8 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2029
Figure 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m), 2018
Figure 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 4.3 Retinal Disorder Drugs Market: Revenue Forecast ($m) by Leading Drugs, 2019-2029
Figure 4.4 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2018
Figure 4.5 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2023
Figure 4.6 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2029
Figure 4.7 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2019-2029
Figure 4.8 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2019-2029
Figure 4.9 Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2019-2029
Figure 4.10 Visudyne: Sales Forecast ($m, AGR%), 2018-2029
Figure 4.11 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2018-2029
Figure 4.12 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2019-2029
Figure 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2018
Figure 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 5.3 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2019-2029
Figure 5.4 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2018
Figure 5.5 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2023
Figure 5.6 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2028
Figure 5.7 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2018-2029
Figure 5.8 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2019-2029
Figure 5.9 Vigamox: Novartis Sales Forecast ($m, AGR%), 2019-2029
Figure 5.10 TobraDex: Sales Forecast ($m, AGR%), 2019-2029
Figure 5.11 Cravit: Sales Forecast ($m, AGR%), 2019-2029
Figure 5.12 Acular: Sales Forecast ($m, AGR%), 2018-2029
Figure 5.13 AzaSite: Akorn Sales Forecast ($m, AGR%), 2018-2028
Figure 5.14 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2019-2029
Figure 6.1 Leading Glaucoma Drugs: Revenue ($m), 2018
Figure 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 6.3 Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2019-2029
Figure 6.4 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2018
Figure 6.5 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2023
Figure 6.6 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2029
Figure 6.7 Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2018-2029
Figure 6.8 Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2019-2029
Figure 6.9 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2019-2029
Figure 6.10 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2019-2029
Figure 6.11 Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2019-2029
Figure 6.12 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2019-2029
Figure 6.13 Azopt: Novartis Sales Forecast ($m, AGR%), 2019-2029
Figure 6.14 Tapros: Santen Sales Forecast ($m, AGR%), 2018-2029
Figure 6.15 Zioptan: Akorn Sales Forecast ($m, AGR%), 2019-2029
Figure 6.16 Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2019-2029
Figure 7.1 Leading Dry Eye Drugs: Revenue ($m), 2018
Figure 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 7.3 Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2019-2029
Figure 7.4 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2018
Figure 7.5 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2023
Figure 7.6 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2029
Figure 7.7 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2019-2029
Figure 7.8 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2019-2029
Figure 7.9 Hyalein: Santen Sales Forecast ($m, AGR%), 2018-2029
Figure 7.10 Diquas: Santen Sales Forecast ($m, AGR%), 2018-2029
Figure 7.11 Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
Figure 7.12 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2019-2029
Figure 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2018
Figure 8.2 US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2019-2029
Figure 8.3 Brazil, Russia and India Ophthalmic Drugs Market: Market Forecast ($m), 2018-2029
Figure 8.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2018-2023
Figure 8.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2023-2029
Figure 8.6 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2018
Figure 8.7 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2023
Figure 8.8 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2029
Figure 8.9 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.10 US Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.11 EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2018
Figure 8.12 Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2019-2029
Figure 8.13 EU5 Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.14 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2018
Figure 8.15 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2023
Figure 8.16 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2029
Figure 8.17 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.18 Germany Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.19 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.20 France Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.21 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.22 UK Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.23 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.24 Italy Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.25 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.26 Spain Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.27 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.28 Japan Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.29 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.30 China Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.31 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.32 Brazil Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.33 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.34 Russia Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.35 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.36 India Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 8.37 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
Figure 8.38 ROW Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
Figure 9.1 Leading Ophthalmic Drug Companies: Revenue ($m), 2018
Figure 9.2 Ophthalmic Drugs Market: Market Forecast ($m) by Leading Companies, 2019-2029
Figure 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2018
Figure 9.4 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2023
Figure 9.5 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2029
Figure 9.6 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
Figure 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
Figure 9.8 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 201-2029
Figure 9.9 Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2018-2029
Figure 9.10 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
Figure 9.11 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
Figure 9.12 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
Figure 9.13 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
Figure 9.14 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
Figure 9.15 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
Figure 11.1 World 65+ Population Forecast: Size (m), AGR (%), 2017-2028
Figure 11.2 Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030
Figure 11.3 Porter’s Five Force Analysis of the Ophthalmic Drugs Market, 2017
Figure 12.1 Global Ophthalmic Drugs: Market Forecast ($m), 2018 - 2029
Figure 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2018-2029
Abbott
AbbVie
Actavis
Acucela
Advanced Cell Technologies
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Inc
Alcon
Alimera Sciences
Allegro
Allergan
Amakem
Amgen
Ampio Pharmaceuticals
Apotex Inc
AstraZeneca
Aurobindo Pharma Ltd
Barr Laboratories Inc.
Bausch & Lomb
Bayer
Bicycle Therapeutics
Biocad
BioDiem
BioXpress Therapeutics
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Chiesi Farmaceutici S.p.A
Cipla
Colby Pharmaceutical Company
Daiichi Sankyo
Eleven Biotherapeutics
EyeCyte
EyeGate Pharmaceuticals
ForeSight Biotherapeutics
Gene Signal
Genentech
GSK
iCO Therapeutics
Icon Bioscience
InSite Vision
Inspire Pharmaceuticals
Instituto Terapeutico Delta Ltda
Kala Pharmaceuticals
KalVista
Kestrel Ophthalmics
Kyowa Hakko Kirin
LEO Pharma
MacuCLEAR
Meda
Merck & Co.
MerLion Pharmaceuticals
Morgan Stanley
Neurim Pharmaceuticals
Neurotech
NovaBay
Novartis
Ohr Pharmaceutical
Omeros
OphthaliX
Ophthotech Corporation
Oxigene
PanOptica
Patheon Pharmaceuticals
Pfizer
Pharmacia
Premacure
pSivida
QLT
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
Roche
R-Tech UENO
RXi Pharmaceuticals
Santen
SARcodeBioscience
Seikagaku
Senju
Servier
Shire
Sobi
Spark Therapeutics
SymphonyVIDA
Takeda
Thrombogenics
Upjohn
USV North America
Valeant
Vanda Pharmaceuticals
Warner-Lambert
Watson
Wockhardt
Wyeth Pharmaceuticals
Zach System Spa
List of Organizations Mentioned in the Report
American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
CDSCO (India)
European Union
European Commission
Health Canada (Canada)
Institute of Experimental Medicine
Italian Competition Authority (ICA)
Italian National Health Service
Japanese Ministry of Health, Labour and Welfare (MHLW)
MCC (South Africa)
MHLW (Japan)
MHRA (UK)
PAHO
SFDA (China)
TGA (Australia)
University of Modena
US National Eye Institute (NEI)
World Health Organization (WHO)
WIPO
WTO
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
